Industriepark Mechelen Noord I, Zone L
Generaal De Wittelaan 11 A
562 articles with Galapagos NV
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
Galapagos NV announced randomization of the last patient into the multi-center, globalDIVERSITY Phase 3 study.
Galapagos issued 7,600 new ordinary shares on 20 September 2021, for a total capital increase of €151,787.50.
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Galapagos NV today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca
As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company's share price by 70%.
Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
Galapagos NV (Euronext & Nasdaq: GLPG)reports positive topline resultswith tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b studyin psoriasis patients.GLPG3667 was discovered by Galapagos.
Galapagos NV(Euronext & Nasdaq: GLPG)reports topline results with GLPG3970 in three patientstudies.GLPG3970, the first product candidatefrom a broad portfolio of SIK inhibitor compounds, provides clinicaldatasupporting the role of SIK inhibition in inflammation.
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
While the drug showed significant improvement in patients on a 200mg daily dose of filgotinib, it may not be promoted in the states any time soon.
Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis
Mechelen, Belgium; 10 July 2021, 11.10 CET; Galapagos NV announced new post-hoc analyses from the Phase 3 SELECTION program, supporting the activity and tolerability of filgotinib, a once-daily, oral JAK1 preferential inhibitor, under investigation for the treatment of patients with moderately to severely active ulcerative colitis.
Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions.
Galapagos NV announced that primary and secondary endpoint results from the phase 3 SELECTIONinduction and maintenance study were published in The Lancet00666-8).The study, sponsored by Gilead Sciences, Inc., was designed to assess the efficacy and safety of the once-daily, oral preferential JAK1 inhibitor, filgotinib, under investigation in patients with moderately to severely active ulcerative colitis.
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
Galapagos NV (Euronext & Nasdaq: GLPG) today announced that 15 abstracts,including scientific updates, and data providing further understanding on the profile of filgotinib as a treatment for people with Rheumatoid Arthritis (RA), will be presented at the European League Against Rheumatism (EULAR) virtual congress 2021, 2-5 June.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting
Study uses mobile device technology to support capture of patient-reported outcomes during early and ongoing use of study treatment amongst patients with rheumatoid arthritis
Galapagos NV will refocus its clinical pipeline and make some cost adjustments to save the company €150 million after disappointing studies assessing therapies for rheumatoid arthritis and idiopathic pulmonary fibrosis.
Mechelen, Belgium; 06May 2021, 22.01 CET; regulated information – Galapagos NV announces its unaudited Q1results and operational highlights, which are further detailed in theQ12021report available on the Galapagos website, www.glpg.com.
Mechelen, Belgium;30 April 2021, 22.01 CET; regulated information –– Galapagos NV announced that its supervisory board created 2,736,250subscription rights under new subscription rightplans for the benefit of the personnelof the company and its subsidiaries.
Belgium-based Galapagos NV and Foster City, California-based Gilead Sciences halted the ISABELA Phase III clinical trial of ziritaxestat in idiopathic pulmonary fibrosis.
Galapagos NV and Selvita S.A. announced that the strategic transaction in which Selvita has acquired Fidelta from Galapagos has been completed.
A little more than one year after Gilead Sciences and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies have pulled the plug on that goal.